Synergistic co-administration of doxorubicin and berberine by PLGA/PVA hybrid polymeric Nanoformulation for breast cancer treatment
- سال انتشار: 1404
- محل انتشار: مجله علوم نانو، دوره: 12، شماره: 2
- کد COI اختصاصی: JR_NAMJ-12-2_006
- زبان مقاله: انگلیسی
- تعداد مشاهده: 112
نویسندگان
Department of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Department of Medical Nanotechnology, School of Medicine, North Khorasan University of Medical Sciences, Bojnūrd, Iran
چکیده
Objective(s): The clinical application of doxorubicin (DOX), a potent anticancer agent, is restricted by its serious side-effects and multidrug resistance. The combination strategy of antineoplastic drugs with Berberine (BBR) as plant-derived natural products enhances the cytotoxicity of chemotherapeutic drugs in cancer cells and also amends their toxicity in normal cells. Materials and Methods: In this study, the nanoparticles (NPs) of PLGA/PVA containing DOX and BBR were synthesized and optimized using the double emulsion-solvent evaporation method. The vesicular size, zeta potential, entrapment efficiency and also the drug release profile was surveyed at different temperatures and pH (۳۷ °C, ۷.۴ and ۴۲ °C, ۵.۲). The MTT assay was used to evaluate the cytotoxic effects of individual of DOX and BBR as a free form and as a nanoparticle form and also the combination of DOX- and BBR-loaded NPs on MCF-۷ breast cancer cells. Results: The optimum formulation demonstrated that the vesicle size and zeta potential of DOX were ۱۷۶.۴ nm and -۵۶.۴ mV and BBR were ۱۵۰.۳ nm and -۴۱.۲ mV, respectively. Entrapment efficiency (EE%) for DOX and BBR was ۹۱.۰ ± ۱.۹% and ۸۲.۰ ± ۱.۸%, respectively. The DOX- and BBR -loaded NPs exhibited a sustained and controlled release pattern with the pH- and thermosensitive characteristic. Additionally, the loading of DOX and BBR into PLGA/PVA NPs had a higher toxicity against cancer cells when compared with free forms and the combination of DOX and BBR was exhibited an augmented antineoplastic activity against the cancer cell death. Conclusion: The findings of this study suggest that the coadministration of DOX with BBR using the PLGA/PVA NPs may have the potential clinical application in sensitization cells to DOX and generates synergistic antitumor effects.کلیدواژه ها
Berberine, Breast Cancer, Doxorubicin, PLGA, PVAاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.